Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 59, Issue -, Pages 1-8Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2021.02.001
Keywords
Innovative therapy; Targeted therapy
Categories
Ask authors/readers for more resources
Experts at the Tenth Edition of the Annual Congress on Anticancer Innovative Therapy shared the latest knowledge and novel therapeutic approaches in fields such as immuno-oncology, epigenetics, cancer metabolism, cancer stem cells, tumor cell signaling, and the immune system. The conference also discussed possible mechanisms of resistance to these innovative therapies, particularly with respect to immune checkpoint blockers (ICB), providing a broad overview of future challenges and hopes for improving cancer treatment in the medium-short term.
During the Tenth Edition of the Annual Congress on Anticancer Innovative Therapy [Milan, 23/24 January 2020], experts in the fields of immuno-oncology, epigenetics, tumor cell signaling, and cancer metabolism shared their latest knowledge on the roles of i] epigenetics, and in particular, chromatin modifiers, ii] cancer metabolism, iii] cancer stem cells [CSCs], iv] tumor cell signaling, and iv] the immune system. The novel therapeutic approaches presented included epigenetic drugs, cell cycle inhibitors combined with ICB, antibiotics and other off-label drugs, small-molecules active against CSCs, liposome-delivered miRNAs, tumor-specific CAR-T cells, and T-cell-based immunotherapy. Moreover, important evidence on possible mechanisms of resistance to these innovative therapies were also discussed, in particular with respect to resistance to ICB. Overall, this conference provided scientists and clinicians with a broad overview of future challenges and hopes to improve cancer treatment reasonably in the medium-short term.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available